Related papers: The dose-dense principle in chemotherapy
Phase I dose-escalation trials must be guided by a safety model in order to avoid exposing patients to unacceptably high risk of toxicities. Traditionally, these trials are based on one type of schedule. In more recent practice, however,…
Biosyntheses of proteins, nucleotides and fatty acids, are essential for the malignant proliferation and survival of cancer cells. Cumulating research findings show that amino acid restrictions are potential strategies for cancer…
A distributed optimal control problem for a diffuse interface model, which physical context is that of tumour growth dynamics, is addressed. The system we deal with comprises a Cahn--Hilliard equation for the tumour fraction coupled with a…
The appearance of a new dangerous and contagious disease requires the development of a drug therapy faster than what is foreseen by usual mechanisms. Many drug therapy developments consist in investigating through different clinical trials…
Resistance to therapy remains a significant challenge in cancer treatment, often due to the presence of a stem-like cell population that drives tumor recurrence post-treatment. Moreover, many anticancer therapies induce plasticity,…
Cancer is a disease that takes millions of lives every year. Then, to propose treatments, avoid recurrence, and improve the patient's life quality, we need to analyze this disease from a biophysical perspective with a solid mathematical…
The concept of personalised medicine in cancer therapy is becoming increasingly important. There already exist drugs administered specifically for patients with tumours presenting well-defined mutations. However, the field is still in its…
Cardiotoxicity induced by cancer treatment has become a major clinical concern, affecting the long-term survival and quality of life of cancer patients. Effective clinical decision-making, including the detection of cancer treatment-induced…
While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high risk disease. In this work, we use a mathematical…
Multidrug resistance consists of a series of genetic and epigenetic alternations that involve multifactorial and complex processes, which are a challenge to successful cancer treatments. Accompanied by advances in biotechnology and…
Tracking and characterizing the blood uptake process within solid pancreatic tumors and the subsequent spatio-temporal distribution of red blood cells are critical to the clinical diagnosis of the cancer. This systematic computational study…
We consider an evolutionary PDE system coupling the Cahn-Hilliard equation with singular potential, mass source and transport effects, to a Brinkman-type relation for the macroscopic velocity field and to a further equation describing the…
Despite recent advances in the field of Oncoimmunology, the success potential of immunomodulatory therapies against cancer remains to be elucidated. One of the reasons is the lack of understanding on the complex interplay between tumor…
The aim is to create a method for accurately estimating the duration of post-cancer treatment, particularly focused on chemotherapy, to optimize patient care and recovery. This initiative seeks to improve the effectiveness of cancer…
Cancer Biotherapy (CB), as opposed to cancer chemotherapy, is the use of macromolecular, biological agents instead of organic chemicals or drugs to treat cancer. Biological agents usually have higher selectivity and have less toxic side…
We consider a dose-optimization design for first-in-human oncology trial that aims to identify a suitable dose for late-phase drug development. The proposed approach, called the Pharmacometrics-Enabled DOse OPtimization (PEDOOP) design,…
The spread of metastases is a crucial process in which some questions remain unanswered. In this work, we focus on tumor cells circulating in the bloodstream, the so-called Circulating Tumor Cells (CTCs). Our aim is to characterize their…
Deep learning has facilitated the automation of radiotherapy by predicting accurate dose distribution maps. However, existing methods fail to derive the desirable radiotherapy parameters that can be directly input into the treatment…
Imaging in clinical oncology trials provides a wealth of information that contributes to the drug development process, especially in early phase studies. This paper focuses on kinetic modeling in DCE-MRI, inspired by mixed-effects models…
Cell heterogeneity plays an important role in patient responses to drug treatments. In many cancers, it is associated with poor treatment outcomes. Many modern drug combination therapies aim to exploit cell heterogeneity, but determining…